Trial Profile
An Open-label, Multi-center Phase I Dose-finding Study of RAD001 (Everolimus, Afinitor) in Combination With BEZ235 in Patients With Advanced Solid Tumors.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Dactolisib (Primary) ; Everolimus (Primary)
- Indications Advanced breast cancer; Male breast cancer; Renal cell carcinoma; Solid tumours
- Focus Adverse reactions
- Sponsors Novartis
- 01 Mar 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 18 Nov 2014 Planned End Date changed from 1 Aug 2014 to 1 Apr 2015 as reported by ClinicalTrials.gov.
- 18 Nov 2014 Planned primary completion date changed from 1 Aug 2014 to 1 Apr 2015 as reported by ClinicalTrials.gov.